SG11201901125TA - Treatment of dementia - Google Patents
Treatment of dementiaInfo
- Publication number
- SG11201901125TA SG11201901125TA SG11201901125TA SG11201901125TA SG11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- aberdeen
- aberdeenshire
- wista
- institute
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 abstract 1
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004640 memantine Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000000946 synaptic effect Effects 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111 010 1111 001110 11111111111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/041739 Al 08 March 2018 (08.03.2018) WI P0 I P C T (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 31/5415 (2006.01) A61K 31/55 (2006.01) kind of regional protection available): ARIPO (BW, GH, A61K 45/06 (2006.01) A61K 9/20 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, A61K 31/136 (2006.01) A61K 9/48 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61K 31/165 (2006.01) A61P 25/28 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, A61K 31/445 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/EP2017/071437 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 25 August 2017 (25.08.2017) Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (25) Filing Language: English (26) Publication Language: English Published: — with international search report (Art. 21(3)) (30) Priority Data: 1614834.8 01 September 2016 (01.09.2016) GB (71) Applicant: WISTA LABORATORIES LTD. [SG/SG]; 25 Bukit Batok Crescent, The Elitist #06-13, Singapore 658066 (SG). _ (71) Applicant (for MG only): HARRINGTON, Charles — Robert [GB/GB]; WisTa Laboratories Ltd., Institute of = Medical Sciences, Forresterhill, Aberdeen Aberdeenshire = AB25 2ZD (GB). Inventors: WISCHIK, Claude Michel; c/o WisTa Lab- (72) = oratories Ltd., Institute of Medical Sciences, Forresterhill, _= = Aberdeen Aberdeenshire AB25 2ZD (GB). SCHELTER, Bjorn Olaf; c/o University of Aberdeen, Institute for Corn- _ = plex Systems and Mathematical Biology, Meston Walk., Aberdeen Aberdeenshire AB24 3UE (GB). WISCHIK, Damon Jude; c/o Cambridge Big Data, Cavendish Labo- ratory, J.J. Thomson Avenue, Cambridge Cambridgeshire — = CB3 OHE (GB). STOREY, John Mervyn David; c/o WisTa Laboratories Ltd., Department of Chemistry, Meston = — = Walk, Old Aberdeen Aberdeenshire AB24 3UE (GB). — — Agent: KREMER, Simon et al.; Mewburn Ellis LLP, City (74) Tower, 40 Basinghall Street, London Greater London EC2V = 5DE (GB). = = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, — 1-1 01 M KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, IN TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1-1 71' 0 00 (54) Title: TREATMENT OF DEMENTIA 1-1 0 (57) : The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium ei compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic 0 Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901125TA true SG11201901125TA (en) | 2019-03-28 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901125TA SG11201901125TA (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (en) |
| EP (1) | EP3506904B1 (en) |
| JP (1) | JP7066679B2 (en) |
| KR (1) | KR102559354B1 (en) |
| CN (1) | CN109890391B (en) |
| AU (1) | AU2017318333B2 (en) |
| CA (1) | CA3034625A1 (en) |
| DK (1) | DK3506904T3 (en) |
| ES (1) | ES2847929T3 (en) |
| GB (1) | GB201614834D0 (en) |
| HR (1) | HRP20210162T1 (en) |
| MX (1) | MX384442B (en) |
| MY (1) | MY187564A (en) |
| PL (1) | PL3506904T3 (en) |
| PT (1) | PT3506904T (en) |
| SG (1) | SG11201901125TA (en) |
| SI (1) | SI3506904T1 (en) |
| WO (1) | WO2018041739A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100983301B1 (en) | 2006-03-29 | 2010-09-20 | 위스타 레보레이토리스 리미티드 | 3,7-diamino-10H-phenothiazine salt and uses thereof |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| CN109789148A (en) | 2016-07-25 | 2019-05-21 | 维斯塔实验室有限公司 | Administration and dosage of diaminophenothiazines |
| ES2989458T3 (en) | 2018-07-26 | 2024-11-26 | Wista Lab Ltd | Optimized dosage of diaminophenothiazines in populations |
| AU2018440060B2 (en) | 2018-09-05 | 2025-04-10 | Genting Taurx Diagnostic Centre Sdn Bhd | Network methods for neurodegenerative diseases |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| EP4146225B1 (en) * | 2020-05-05 | 2024-10-09 | WisTa Laboratories Ltd. | Methylthioninium compounds for use in the treatment of hypoxemia |
| AU2023279800A1 (en) | 2022-05-31 | 2024-12-19 | TauRx Therapeutics Management Ltd | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| WO2024178120A2 (en) * | 2023-02-21 | 2024-08-29 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2003101458A1 (en) * | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| PT2322517T (en) | 2004-09-23 | 2019-07-30 | Wista Lab Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| KR100983301B1 (en) * | 2006-03-29 | 2010-09-20 | 위스타 레보레이토리스 리미티드 | 3,7-diamino-10H-phenothiazine salt and uses thereof |
| MY172157A (en) | 2006-03-29 | 2019-11-15 | Wista Lab Ltd | Thioninium compounds and their use |
| FR2899107B1 (en) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | USE OF (S) -ROSCOVITINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (en) | 2006-07-12 | 2011-02-11 | Provence Technologies | PROCESS FOR PURIFYING DIAMINOPHENOTHIAZIUM COMPOUNDS |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| PL2167095T3 (en) * | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Phenothiazine compounds for treating mild cognitive impairment |
| EP2954932B1 (en) * | 2007-10-03 | 2018-09-19 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| BR112012006638B1 (en) | 2009-09-24 | 2020-05-26 | Wista Laboratories Ltd. | FORM C OF METHYLTHYLINUM CHLORIDE DIHYDRATE, ITS PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION |
| MX2012003035A (en) | 2009-09-24 | 2012-06-12 | Wista Lab Ltd | Process. |
| JP5898701B2 (en) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | Phenothiazinediaminium salts and their use |
| CN102936244B (en) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | Tacrine-phenothiazine isodiad compound and preparation method thereof |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/en active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/en unknown
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/en unknown
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 PT PT177618428T patent/PT3506904T/en unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/en active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/en unknown
- 2017-08-25 PL PL17761842T patent/PL3506904T3/en unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 ES ES17761842T patent/ES2847929T3/en active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/en active Active
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3506904A1 (en) | 2019-07-10 |
| GB201614834D0 (en) | 2016-10-19 |
| EP3506904B1 (en) | 2020-12-09 |
| US20190192530A1 (en) | 2019-06-27 |
| PL3506904T3 (en) | 2021-07-26 |
| KR102559354B1 (en) | 2023-07-26 |
| JP7066679B2 (en) | 2022-05-13 |
| CN109890391B (en) | 2023-01-31 |
| KR20190045273A (en) | 2019-05-02 |
| SI3506904T1 (en) | 2021-03-31 |
| CN109890391A (en) | 2019-06-14 |
| JP2019526571A (en) | 2019-09-19 |
| MY187564A (en) | 2021-09-30 |
| AU2017318333A1 (en) | 2019-04-18 |
| WO2018041739A1 (en) | 2018-03-08 |
| US10842796B2 (en) | 2020-11-24 |
| PT3506904T (en) | 2021-02-02 |
| MX2019002429A (en) | 2019-07-08 |
| AU2017318333B2 (en) | 2023-05-11 |
| MX384442B (en) | 2025-03-14 |
| HRP20210162T1 (en) | 2021-03-19 |
| DK3506904T3 (en) | 2021-01-04 |
| ES2847929T3 (en) | 2021-08-04 |
| CA3034625A1 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901125TA (en) | Treatment of dementia | |
| SG11201900228YA (en) | Administration and dosage of diaminophenothiazines | |
| SG11201807741SA (en) | Conductive structures, systems and devices including conductive structures and related methods | |
| SG11201908075UA (en) | A microneedle device | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901210UA (en) | Ferroelectric memory cells | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809376WA (en) | Self assembled patterning using patterned hydrophobic surfaces | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201809822SA (en) | Atropine-containing aqueous composition | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900773RA (en) | Methods for optical micropatterning of hydrogels and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |